Treatment of skeletal Erdheim–Chester disease with zoledronic acid: case report and proposed mechanisms of action

@article{Srikulmontree2006TreatmentOS,
  title={Treatment of skeletal Erdheim–Chester disease with zoledronic acid: case report and proposed mechanisms of action},
  author={Thitinan Srikulmontree and Hugh Davis Massey and William Neal Roberts},
  journal={Rheumatology International},
  year={2006},
  volume={27},
  pages={303-307}
}
Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by tissue infiltration of lipid-laden macrophages, multinucleated giant cells, and inflammatory infiltrate of lymphocytes and histiocytes. The disease typically involves long bone, but may also affect the central nervous system, the orbit, retroperitoneal organs, and the lungs. Patients with visceral involvement tend to have poorer outcome. There is no proven effective treatment for ECD to date. However… CONTINUE READING